Literature DB >> 16565883

Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.

Wojciech Krzyzanski1, Sukyung Woo, William J Jusko.   

Abstract

Indirect pharmacodynamic response (IDR) models were developed for agents which alter the generation of cell populations with arbitrary lifespan distributions. These models extend lifespan based IDR models introduced previously [J. Pharmacokinet. Biopharm. 27: 467, 1999] for cell populations with the same lifespan ("delta" distribution). Considered are cell populations exhibiting time-invariant lifespan distributions described by the probability density function l(tau). It is assumed that cell response (R) is produced at a zero-order rate (kin(t)) and is eliminated from the population when the cell lifespan expires. The cell loss rate is calculated as kin*l(t), where '*' denotes the convolution operator. Therapeutic agents can stimulate or inhibit production rates according to the Hill function: 1 +/- H(C(t)) where H(C(t)) contains the capacity (Smax) and potency (SC50) parameters and C(t) is a pharmacokinetic function. The production rate is kin(t) = kin.[ 1+/-H(C(t))]. The operational model is dR/dt = kin(t)-kin*l(t) with the baseline condition R0 = kin.TR, where TR is the mean lifespan. Single populations as well as populations with precursors were examined by simulation to establish the role of lifespan distribution parameters (mean and standard deviation) in controlling the response vs. time profile. Estimability of parameters was assessed. Numerical techniques of solving differential equations with the convolution integral were proposed. In addition, the models were applied to literature data to describe the stimulatory effects of single doses of recombinant human erythropoietin on reticulocytes in blood. The estimates of Smax and SC50 for these agents were obtained along with means and standard deviations for reticulocyte lifespan distributions. The proposed models can be used to analyze the pharmacodynamics of agents which alter natural cell production yielding parameters describing their efficacy and potency as well as means and standard deviations for cell lifespan distributions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565883     DOI: 10.1007/s10928-006-9007-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  23 in total

1.  Population cell life span models for effects of drugs following indirect mechanisms of action.

Authors:  Juan J Perez-Ruixo; Hui C Kimko; Andrew T Chow; Vladimir Piotrovsky; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

2.  Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.

Authors:  Wojciech Krzyzanski; Jacek Dmochowski; Nobuko Matsushima; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-08-29       Impact factor: 2.745

3.  Kinetics of reticulocyte maturity fractions and indices and iron status during therapy with epoetin beta (recombinant human erythropoietin) in cardiac surgery patients.

Authors:  O Sowade; B Sowade; K Brilla; W Franke; P Stephan; J Gross; P Scigalla; H Warnke
Journal:  Am J Hematol       Date:  1997-06       Impact factor: 10.047

4.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics.

Authors:  Y N Sun; W J Jusko
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

5.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

6.  The estimation of blood platelet survival. I. General principles of the study of cell survival.

Authors:  E A Murphy; M E Francis
Journal:  Thromb Diath Haemorrh       Date:  1969-11-15

7.  Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

Authors:  L E Friberg; A Freijs; M Sandström; M O Karlsson
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

8.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

9.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.

Authors:  Wojciech Krzyzanski; William J Jusko; Mary C Wacholtz; Neil Minton; Wing K Cheung
Journal:  Eur J Pharm Sci       Date:  2005-11       Impact factor: 4.384

10.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.

Authors:  Rohini Ramakrishnan; Wing K Cheung; Mary C Wacholtz; Neil Minton; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

View more
  22 in total

1.  Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.

Authors:  Nageshwar R Budha; Andreas Kovar; Bernd Meibohm
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

2.  A semi-mechanistic red blood cell survival model provides some insight into red blood cell destruction mechanisms.

Authors:  Julia Korell; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-18       Impact factor: 2.745

3.  Solution and implementation of distributed lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-11-01       Impact factor: 2.745

4.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

5.  Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.

Authors:  Gilbert Koch; Wojciech Krzyzanski; Juan Jose Pérez-Ruixo; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-21       Impact factor: 2.745

Review 6.  Lifespan based indirect response models.

Authors:  Wojciech Krzyzanski; Juan Jose Perez Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-03       Impact factor: 2.745

7.  Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.

Authors:  Mohammad I Saleh; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-01-10       Impact factor: 1.627

Review 8.  Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels.

Authors:  Kyoung Ah Min; Xinyuan Zhang; Jing-yu Yu; Gus R Rosania
Journal:  Biopharm Drug Dispos       Date:  2013-12-10       Impact factor: 1.627

9.  Reticulocyte-based estimation of red blood cell lifespan.

Authors:  Wojciech Krzyzanski; Michael E Brier; Timothy M Creed; Adam E Gaweda
Journal:  Exp Hematol       Date:  2013-05-24       Impact factor: 3.084

10.  Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.

Authors:  Mohammad I Saleh; Demet Nalbant; John A Widness; Peter Veng-Pedersen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.